Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Drug From Daiichi Sankyo Boosts Japan's OTC Market

This article was originally published in PharmAsia News

Executive Summary

In 2007, the Japanese OTC market grew by 2.3 percent to ¥700 billion, a reversal from a downward trend in recent years. New drugs such as Daiichi Sankyo's Transino contributed to the growth. A liver spots improving drug, Transino has activated the market for products treating pigment spots with sales increasing from ¥10 billion to ¥17 billion. Next year, Tokyo based SSP, a subsidiary of Boehringer Ingelheim, will market drugs made of western herbs such as gingko biloba and grape leaves. Taisho Pharmaceuticals also signed contacts with a German company to introduce similar products. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069009

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel